Oct 01, 09
|
| NEW STORY |
| 07:00 ET |
Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
|
|
Mar 09, 09
|
| 09:35 ET |
Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
|
|
Aug 11, 08
|
| 08:30 ET |
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
|
|
Jun 10, 08
|
| 15:00 ET |
Merrimack Pharmaceuticals Raises $60 Million in Private Financing
|
|
Mar 14, 08
|
| 12:00 ET |
Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
|
|
Nov 29, 07
|
| 15:00 ET |
Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
|
|
Jul 23, 07
|
| 10:00 ET |
Merrimack Pharmaceuticals Names William Slichenmyer, M.D. Senior Vice President and Chief Medical Officer
|
|
Jun 26, 07
|
| 09:30 ET |
Merrimack Pharmaceuticals Names Lisa Evren Senior Vice President and Chief Financial Officer
|
|
Jun 12, 07
|
| 08:30 ET |
Merrimack Pharmaceuticals Receives U.S. Patent Covering Composition of Matter for Recombinant, Non-Glycosylated Human Alpha-fetoprotein; Extends Patent Protection of Lead Product, MM-093, into 2025
|
|
Apr 17, 07
|
| 08:30 ET |
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
|
|
Apr 04, 07
|
| 08:30 ET |
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 2 Pilot Study of MM-093 in Patients with Autoimmune Uveitis
|
|
Jul 17, 06
|
| 07:00 ET |
Merrimack Pharmaceuticals Announces the Addition of Louis Weiner, M.D., to its Scientific Advisory Board
|
|
May 15, 06
|
| 07:00 ET |
Merrimack Pharmaceuticals Announces Two Additions to its Board of Directors
|
|
May 03, 06
|
| 07:00 ET |
Merrimack Pharmaceuticals Names Fazal Khan, Ph.D., Vice President of Manufacturing
|
|
Apr 19, 06
|
| 07:00 ET |
Merrimack Pharmaceuticals Completes Enrollment for Phase 2 Trial of MM-093 In Patients With Psoriasis
|
|
Apr 03, 06
|
| 07:03 ET |
Merrimack Pharmaceuticals Raises $65 Million in Private Financing
|
|
Feb 28, 06
|
| 07:04 ET |
Merrimack Pharmaceuticals Announces the Addition of Barrett Rollins, MD, PhD to its Scientific Advisory Board
|
|
Oct 19, 05
|
| 07:02 ET |
Merrimack Pharmaceuticals Completes Enrollment for Phase 2 Trial of MM-093 in Patients With Rheumatoid Arthritis
|
|
Oct 13, 05
|
| 07:00 ET |
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 2 Study of MM-093 in Patients with Psoriasis
|
|
May 24, 05
|
| 07:01 ET |
Merrimack Pharmaceuticals Announces the Addition of Two New Members to its Scientific Advisory Board
|
|
May 03, 05
|
| 07:05 ET |
Merrimack Pharmaceuticals Appoints Gary L. Crocker as Chairman of the Board
|
|
Apr 20, 05
|
| 07:06 ET |
Merrimack Pharmaceuticals Closes on $37 Million of Series D Equity and Loan Financing
|
|
Mar 03, 05
|
| 07:04 ET |
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
|
|
Aug 25, 04
|
| 07:02 ET |
Merrimack Pharmaceuticals Completes Enrollment for Phase IIa Study of MM-093 in Patients with Rheumatoid Arthritis
|
|
Jul 20, 04
|
| 07:07 ET |
Merrimack Pharmaceuticals Names Dr. Brian L. Hamilton Vice President of Clinical and Regulatory Affairs
|
|
Jun 01, 04
|
| 07:04 ET |
Merrimack Pharmaceuticals Begins Exploratory Collaboration with Novartis Institutes for Biomedical Research
|
|
May 04, 04
|
| 07:04 ET |
Merrimack Pharmaceuticals Closes $28 Million Series C Financing Round
|
|
| 07:04 ET |
Merrimack Pharmaceuticals Welcomes Gary L. Crocker to the Board of Directors
|
|